Oral penicillin has a number of disadvantages in the treatment of gonorrhoea; absorption is uncertain and there is no guarantee that the patient will take the tablets in the prescribed amounts or at the proper times. If apparent cure results quickly there is also the danger that some of the tablets may be retained with a subsequent temptation towards self-medication with subcurative doses on a future occasion, and an encouragement of "black market" activity.
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On the other hand, the advantages are obvious for those persons who really dislike injections, and the speed of administration is much quicker if the oral route is used. Also severe penicillin reactions in allergic patients tend to be less severe when the antibiotic is given orally rather than by injection.
Many of the objections to oral therapy are removed if the treatment can be administered in one single dose under supervision in the clinic. Failing this, if one dose is given in the clinic and the patient is then given a second to take after a few hours, this will probably be taken. In a previous paper (Willcox, 1958) , the use of phenoxymethyl penicillin (penicillin V) in gonorrhoea was described. This penicillin given by mouth was said to produce higher and more prolonged serum levels dose for dose than had previously been possible with the available penicillin preparations. Using 2-3 mega units (1-25-1-87 g.) of penicillin V in one or two doses, there were no failures in 33 white patients, but there were 28-6 per cent. of apparent failures in 49 followed out of 52 coloured patients.
Since this time there have been new developments (Lancet, 1959) . Following the work in the U.S.A. of J. C. Sheehan, who first converted penicillin G to 6-aminopenicillanic acid (and who synthesised penicillin V), the English workers, Doyle and Robinson, * Received for publication July 3, 1961. found an economic source of this compound in fermentation broths, and made possible the synthesis of innumerable penicillin compounds. One such compound is "Broxil", the potassium salt of 6-(phenoxyproprionamide)-penicillanic acid (otherwise known as "Syncillin" or BL P152). It is claimed that its antibiotic activity is slightly greater than that of penicillin V and that it gives blood levels substantially higher than with penicillin V. This new penicillin has been investigated in the treatment of acute gonorrhoea.
Case Material A total of 148 male patients with uncomplicated gonorrhoea have been treated with 6-(phenoxy-proprionamide)-penicillanic acid ("Broxil") as the potassium salt given orally. Of the 148 patients, 89 were Negroes (eighty from the West Indies, seven from West Africa, one from the Sudan, and one from Venezuela), 41 were from the United Kingdom, eleven from Eire, two from Hungary, and one each from France, Greece, India, Pakistan, and Poland. 118 men were single, 29 married, and one divorced. Their average age was 27-6 years (being 26 -years for the Negroes and 29 9 years for the remainder).
53 had had no previous venereal incident but the remaining 95 had had no less than 200 previous attacks of gonorrhoea, forty of non-gonococcal urethritis, five of syphilis, five of venereophobia, two of scabies, and one each of condylomata acuminata, herpes genitalis, and unspecified penile sore (255 previous incidents). Among the 89 Negroes, 27 had had no previous incident, but the remaining 62 had had 142 previous attacks of gonorrhoea, 32 of non-gonococcal urethritis, two of syphilis, two of venereophobia, and one each of herpes genitalis, unspecified penile sore, and scabies (181 previous incidents). One West Indian patient accounted 23 previous attacks of gonorrhoea and five of non-gonococcal urethritis. The average number of previous attacks was thus two The patients were followed-up for varying periods of from 1 week to 3 months. No satisfactory criteria exist to distinguish relapse from re-infection apart from a history of further sexual exposure, which may or may not be admitted,-and, even when risk is admitted, it is not always possible to secure the consort for examination. However, it is interesting to observe that in all but one of the cases which were judged to be treatment failures, gonococci were again noted in the urethral smear within 2 weeks from therapy, and that in all but one of the cases in which re-infection was suspected the recurrence took place more than 2 weeks from therapy.
Results
The results of treatment are summarized in Table I . The failure rate was highest (27-3 per cent.) when a single dose of 1 g. was given. When two doses each of 0 75-1 g. were given 6 hours apart, the failure rates were less (12-8-16-3 per cent.). However, there seemed to be no advantage in increasing the total dose from 1 * 5 g. to 2 g. when using the double-dose technique.
In all, there were twenty suspected failures and seventeen re-infections. There were also nine instances of non-gonococcal infection. One patient treated with 1 5 g. developed dark-field positive sero-negative primary syphilis 24 days after treatment which thus had no effect on the incubating syphilis in this case.
Only one patient (given two doses of 1 g.) complained of side-effects, and he had nausea and diarrhoea for 2 to 3 days following treatment.
There was no significant difference in the failure rates experienced in the white and negro groups (Table II, opposite) .
Discussion
Few data are so far available in Britain concerning the effects of "Broxil" in gonorrhoea. Jefferiss and Rosedale (1961) treated 100 patients with a total dosage of 1 g. at an interval of 4 to 8 hours. There were twelve failures. In the current series, in which two doses were used, an interval of 6 hours was chosen so as to enable patients seen before 6 p.m. to complete their treatment before midnight.
Calculated on the basis of patients treated regardless of follow-up, the failure rates in this series would be 24 0 per cent. with a single dose of 1 g., 10 5 per cent. with two doses each of 0 75 g., and 12 1 per cent. with two doses each of 1 g. Jefferiss and Rosedale (1961) treated a further Summary and Conclusions (1) The need is stressed for oral therapy in gonorrhoea which will be effective in a single dose, or at the most two doses.
(2) The results of treating 148 male cases of uncomplicated gonorrhoea with 6-(phenoxyproprionamide)-penicillanic acid ("Broxil") in a dosage of 1-2 g. given as one or two doses are outlined. In 25 patients given a single dose of 1 g., the failure rate was 27-3 per cent. of those followed. In 57 patients given two doses of 0-75 g. each at an interval of 6 hours, the failure rate was 12-8 per cent. In 66 patients given two doses of' 1 g. each at the same interval, the failure rate was 16-3 per cent. of those followed. There seemed to be no advantage, therefore, in increasing the total dose from 1 5 to 2 g. if two doses were used.
(3) In the entire series only one patient complained of side-effects (gastro-intestinal), although 66 patients received two doses each of 1 g. at an interval of 6 hours.
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